Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex
The objectives of this study were to prepare and characterize inclusion complexes of lovastatin with hydroxypropyl-β-cyclodextrin (HPβ-CD) and to study the effect of the complexes on the dissolution rate of lovastatin (LVS). The findings suggest that LVS's poor dissolution profile can be overcome by preparing its inclusion complex with HPβ-CD.


Pharmaceutical Technology


Acknowlegment

The authors thank Roquette Frères, France for a generous gift of HPβ-CD. The authors thank Lincoln Pharmaceuticals Ltd. and Maan Pharmaceuticals Ltd., India for providing lovastatin and various formulation excipients, respectively as gift samples. The authors are grateful to the Department of Pharmacy, M.S. University, India for conducting differential scanning calorimetry studies and to Sun Pharmaceutical Advance Research Center, India for conducting X-ray diffraction studies of the samples.

Rakesh P. Patel* is an assistant professor and Madhabhai M. Patel is a professor and the head of the department of pharmaceutics, S K Patel College of Pharmaceutical Education and Research, Ganpat University, Ganpat vidyanagar, Kherva 382711, Mehsana, Gujarat, India,

*To whom all correspondence should be addressed.

Submitted: July 10, 2006. Accepted: Oct. 11, 2006.

Keywords: lovastatin, hydroxypropyl-β-cyclodextrin, inclusion complexation, in vitro dissolution studies.

References

1. J.S. MacDonald et al., "Preclinical Evaluation of Lovastatin," Am. J. Cardiol . 62 (15), 16J–27J (1998).

2. E.E. Slater and J.S. MacDonald, "Mechanism of Action and Biological Profile of HMG CoA Reductase Inhibitors: A New Therapeutic Alternative," Drugs 36 (Suppl. 3), 72–82 (1998).

3. S.B. Gerald, K.E Dean, and J.K. Micheal, "Lovastatin," in Analytical Profiles of Drug Substances and Excipients, Vol. 21, G.B. Harry, Ed., (Academic Press, Inc., New York, NY, 1992), pp. 277–315.

4. D.O. Thompson, "Cyclodextrins-Enabling Excipients: Their Present and Future Use in Pharmaceuticals," Crit. Rev. Ther. Drug Carrier Syst. 14 (1), 1–104 (1997).

5. C.M. Fernandes, V.M. Teresa, and F.J. Veiga, "Physicochemical Characterization and In Vitro Dissolution Behavior of Nicardipine-Cyclodextrins Inclusion Compounds," Eur. J. Pharm. Sci. 15 (11), 79–88 (2002).

6. M. Kamada et al., "Cyclodextrin Conjugate-Based Controlled Release System: Repeated- and Prolonged-Releases of Ketoprofen after Oral Administration in Rats," J. Control. Release 82 (2-32-3), 407–416 (2002).

7. K. Uekama and M. Otagiri, "Cyclodextrins in Drug Carrier Systems," Crit. Rev. Ther. Drug Carrier Syst. 3 (1), 1–40 (1987).

8. S. Baboota, M. Dhaliwal, and K. Kohli, "Physicochemical Characterization, In Vitro Dissolution Behavior, and Pharmacodynamic Studies of Rofecoxib-cyclodextrin Inclusion Compounds," AAPS PharmSciTech . 6 (1), E83–E90 (2005).

9. G. S. Tirucherai and A. K. Mitra, "Effect of Hydroxypropyl Beta Cyclodextrin Complexation on Aqueous Solubility, Stability, and Corneal Permeation of Acyl Ester Prodrugs of Ganciclovir," AAPS PharmSciTech. 4 (3), E45 (2003).

10. B. N. Nalluri et al.,"Physicochemical Characterization and Dissolution Properties of Nimesulide-Cyclodextrin Binary Systems," AAPS PharmSciTechnol . 4 (1), E2 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here